TEM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempus AI Inc (TEM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth in revenue, strategic partnerships, and hedge fund interest outweigh the short-term technical weakness and mixed analyst sentiment. The pre-market dip presents a favorable entry point for long-term investors.
The technical indicators suggest a bearish short-term trend. The MACD is negative and expanding downward, RSI is neutral but leaning towards oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 48.878, with key support at 46.074 and resistance at 51.682.
ARK Investment Management purchased $28 million worth of shares, signaling confidence in the company's long-term potential.
Strategic partnerships with Merck, Median Technologies, NYU Langone Health, and Daiichi Sankyo highlight the company's leadership in AI-driven healthcare.
Hedge funds are significantly increasing their positions, with an 884.13% increase in buying activity last quarter.
Insider selling activity by Eric Lefkofsky, who has sold a significant number of shares recently.
Mixed analyst sentiment with several price target reductions following Q4 results.
Pre-market price decline of -1.16%, reflecting short-term market weakness.
In Q4 2025, Tempus AI demonstrated strong growth with an 82.98% YoY revenue increase to $367.2M. Net income improved significantly, up 316.21% YoY, though still negative at -$54.17M. EPS increased by 275% YoY to -0.3, and gross margin rose to 64.73%, up 6.41% YoY. These metrics indicate robust growth and improving financial health.
Analyst sentiment is mixed. H.C. Wainwright raised the price target to $95, citing strategic partnerships and growth potential. However, other firms like Morgan Stanley, JPMorgan, and Stifel lowered their targets, citing valuation concerns and clouded visibility. The consensus remains cautiously optimistic, with several firms maintaining Buy or Outperform ratings.
